Factors Associated With Survival in Patients Having Pneumocystis Jirovecii

Factors Associated With Survival in Patients With a Positive Sample for Pneumocystis Jirovecii at the Strasbourg University Hospital: a Retrospective Study From 2016 to 2018

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06173453

Acronym

JIROVECI

Enrollment

300

Registered

2023-12-15

Start date

2023-01-01

Completion date

2025-10-10

Last updated

2023-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumocystis Jirovecii Infection

Keywords

P jirovecii Infection, Pneumocystis Infections, Pneumocystis jirovecii Infection, Pneumocystis jirovecii, Pneumonia, Pneumocystis

Brief summary

Pneumocystis jirovecii is a fungus that can colonize the airways of some patients and be responsible for a disease called pneumocystosis in other patients and mainly in immunocompromised patients. Pneumocystosis was mainly linked to HIV in the 1990s, but with the advent of new immunosuppressive molecules used in cancers or autoimmune diseases and with the increase in the number of transplants, the epidemiology has changed in recent years. Studies on P. jirovecii-related mortality are only based on patients with pneumocystosis. As a result, patients who are simply colonized or patients who are sick but not treated are not taken into account in these studies. The investigators therefore wish to study the overall mortality at six weeks and at three months in all patients with a positive sample for P. jirovecii

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patients with a positive respiratory sample for P. jirovecii cared for in Strasbourg University Hospitals between 01/01/2016 and 31/12/2018. Positive samples are defined as a direct examination finding cysts or trophozoites after staining with May-Grunewald-Giemsa and/or Gomori-Grocott, a positive P. jirovecii PCR on sputum, tracheal aspirates or bronchial fluid -alveolar * Subject not objecting to the reuse of their data for scientific research purposes.

Exclusion criteria

\- Subject having expressed its opposition to the reuse of its data for scientific research purposes.

Design outcomes

Primary

Measure	Time frame
Survival at six weeks and three months after infection	six weeks after infection

Countries

France

Contacts

Primary ContactFrançois DANION, MD

Francois.danion@chru-strasbourg.fr33 3 69 55 15 88

Outcome results